Kyntra Bio (KYNB) Assets (2014 - 2026)

At the end of FY2025, Kyntra Bio's Assets came in at $119.59 million, down 44.3% from FY2024.

• Annual Assets has declined for eight consecutive years, with a five-year compound annual growth rate of -32.1% (FY2020 to FY2025).
• In prior years, Kyntra Bio's Assets was $214.53 million in FY2024 (-49.3%), $423.53 million in FY2023 (-30.6%), $610.09 million in FY2022 (-21.2%) and $773.82 million in FY2021 (-6.4%).
• The Q2 2026 figure stands as the lowest quarterly Assets in data going back to Q4 2014.
• On a year-over-year basis, Assets has declined in each of the last 19 quarters, with an average decline of 44.4% over the last eight quarters.
• The strongest year-over-year quarter for Assets in the past five years was Q3 2021, with growth of 4.7%; the weakest was Q1 2025, with a decline of 54.8%.
• According to Business Quant data, Assets for the three prior quarters was $109.63 million (Q1 2026), $119.59 million (Q4 2025) and $137.01 million (Q3 2025).